Adalvo showcases Mellozzan®, an EU-approved product designed to alleviate both jet lag and ADHD-related insomnia symptoms.
Mellozzan®, which contains the well-established active substance, Melatonin, is available in capsule and oral solution forms, offering convenient options for patients seeking relief from sleep-related issues.
With MA approvals expected from major European markets in the near future, Mellozzan® presents a high-value product with strong market potential.
In 2023, Mellozzan® contributed to a global Melatonin market of $501 million, with a 3Y CAGR of 10%, according to IQVIA.
Adalvo remains committed to delivering high-quality differentiated products, and Mellozzan® exemplifies our dedication to enhancing patient outcomes.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!